These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35746761)

  • 21. Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures.
    Passer BJ; Wu CL; Wu S; Rabkin SD; Martuza RL
    Gene Ther; 2009 Dec; 16(12):1477-82. PubMed ID: 19693098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus.
    Okubo Y; Uchida H; Wakata A; Suzuki T; Shibata T; Ikeda H; Yamaguchi M; Cohen JB; Glorioso JC; Tagaya M; Hamada H; Tahara H
    J Virol; 2016 Dec; 90(24):11096-11105. PubMed ID: 27707922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
    Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
    J Virol; 2017 May; 91(10):. PubMed ID: 28250120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncolytic HSV: Underpinnings of Tumor Susceptibility.
    Kangas C; Krawczyk E; He B
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of Rab27a as a host factor for oncolytic herpes virus susceptibility to tumor cells.
    Zhou X; Zhao J; Wu Y; Wang L; Ji D; Chen X; Ren P; Zhou GG
    Virus Res; 2021 Jul; 299():198425. PubMed ID: 33905773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Progess on research of herpes simplex virus type 1 mutants for cancer therapy].
    Long Y; Mi Y; Li Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Dec; 25(6):1446-9. PubMed ID: 19166228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody Screening System Using a Herpes Simplex Virus (HSV)-Based Probe To Identify a Novel Target for Receptor-Retargeted Oncolytic HSVs.
    Ikeda H; Uchida H; Okubo Y; Shibata T; Sasaki Y; Suzuki T; Hamada-Uematsu M; Hamasaki R; Okuda K; Yamaguchi M; Kojima M; Tanaka M; Hamada H; Tahara H
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33627393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity.
    Fu X; Rivera A; Tao L; Zhang X
    Mol Ther; 2012 Oct; 20(10):1871-81. PubMed ID: 22692498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. STAT3 activation promotes oncolytic HSV1 replication in glioma cells.
    Okemoto K; Wagner B; Meisen H; Haseley A; Kaur B; Chiocca EA
    PLoS One; 2013; 8(8):e71932. PubMed ID: 23936533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.
    Yoo JY; Pradarelli J; Haseley A; Wojton J; Kaka A; Bratasz A; Alvarez-Breckenridge CA; Yu JG; Powell K; Mazar AP; Teknos TN; Chiocca EA; Glorioso JC; Old M; Kaur B
    Clin Cancer Res; 2012 Sep; 18(18):4931-41. PubMed ID: 22753591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies.
    Bernstock JD; Hoffman SE; Chen JA; Gupta S; Kappel AD; Smith TR; Chiocca EA
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34204248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncolytic herpes simplex virus engineering and preparation.
    Agarwalla PK; Aghi MK
    Methods Mol Biol; 2012; 797():1-19. PubMed ID: 21948465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncolytic Virotherapy by HSV.
    Watanabe D; Goshima F
    Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
    Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
    Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.
    Chen X; Han J; Chu J; Zhang L; Zhang J; Chen C; Chen L; Wang Y; Wang H; Yi L; Elder JB; Wang QE; He X; Kaur B; Chiocca EA; Yu J
    Oncotarget; 2016 May; 7(19):27764-77. PubMed ID: 27050072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and Preliminary Application of a Droplet Digital PCR Assay for Quantifying the Oncolytic Herpes Simplex Virus Type 1 in the Clinical-Grade Production.
    Guo M; Deng L; Liang H; Du Y; Gao W; Tian N; Bi Y; Li J; Ma T; Zhang Y; Wang H
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966.
    Lee TJ; Nair M; Banasavadi-Siddegowda Y; Liu J; Nallanagulagari T; Jaime-Ramirez AC; Guo JY; Quadri H; Zhang J; Bockhorst KH; Aghi MK; Carbonell WS; Kaur B; Yoo JY
    Mol Cancer Ther; 2019 Jun; 18(6):1127-1136. PubMed ID: 30926634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption.
    Bommareddy PK; Peters C; Kaufman HL
    Methods Enzymol; 2020; 635():167-184. PubMed ID: 32122544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.
    Nakashima H; Kaufmann JK; Wang PY; Nguyen T; Speranza MC; Kasai K; Okemoto K; Otsuki A; Nakano I; Fernandez S; Goins WF; Grandi P; Glorioso JC; Lawler S; Cripe TP; Chiocca EA
    J Clin Invest; 2015 Nov; 125(11):4269-80. PubMed ID: 26524593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.